Abstract
Glioblastoma multiforme (GBM) is the most aggressive and prevalent variation of glioma. The first choice treatment is temozolamide (TMZ), an alkylating agent administered orally or intravenously. However, the drug has some limitations, such as the difficulty in crossing the blood-brain barrier (BBB) and the cellular efflux mechanism resistance. As a consequence, the survival rate of pati…